Patient Profile
- Sex / Age:
- Male, 72 years
- Reason for ECG:
- Palpitations and lightheadedness for 36 hours; mild dyspnea on exertion; no chest pain
- Vital signs:
- HR 138 bpm (irregular), BP 142/86, SpO₂ 96%, afebrile
- History:
- Hypertension, type 2 diabetes, hyperlipidemia; no prior known arrhythmia; non-smoker
- Medications:
- Lisinopril, metformin, atorvastatin
- ECG:
- Standard 12-lead, paper speed 25 mm/s, calibration 10 mm/mV
Summary Overview
12-lead ECG demonstrates atrial fibrillation with rapid ventricular response (mean rate ~138 bpm). No ST-segment elevation. Non-specific T-wave changes in the lateral leads, likely rate-related. No acute ischemic features. Stroke-risk score (CHA₂DS₂-VASc) supports anticoagulation.
Calculated Indices
- CHA₂DS₂-VASc:
- 4 (age 72 = 1, hypertension = 1, diabetes = 1, age > 65 already covered; sex M = 0; HF/stroke 0; vascular = 0) — annual stroke risk ~4%/year, anticoagulation indicated [Lip GY, Chest 2010]
- HAS-BLED estimate:
- 1–2 (hypertension; older age soft point) — bleeding risk modest
- QTc (Bazett, average estimated):
- ~430 ms — within normal range
- Reference axis:
- Approximately +30° (normal)
Detailed ECG Findings
Diagnostic Synthesis
-
New-onset atrial fibrillation with rapid ventricular responseConfirmed
Irregularly irregular rhythm without P waves at ventricular rate ~138 bpm in a patient without prior known arrhythmia.
-
Rate-related repolarization abnormalityLikely
ST depression / T-wave flattening commonly resolves with rate control; if persistent after rate control, consider further ischemia evaluation.
-
Acute coronary syndrome (NSTEMI)To Exclude
No ST elevation, no chest pain, but rate-related changes warrant troponin to exclude given age and risk factors.
-
Underlying structural heart diseaseTo Evaluate
Echocardiography recommended to assess LV function and structure as part of standard new-AF workup.
Analytical Summary & Recommendations
Imaging impression
New-onset atrial fibrillation with rapid ventricular response, no acute ischemic ECG features, CHA₂DS₂-VASc 4 supporting anticoagulation.
Recommended next steps
- Rate control: beta-blocker (e.g., metoprolol) or non-dihydropyridine calcium-channel blocker (e.g., diltiazem) targeting resting HR < 110 bpm initially, < 80 bpm if symptomatic [Hindricks G, ESC 2021]
- Anticoagulation: direct oral anticoagulant (DOAC) (e.g., apixaban or rivaroxaban) preferred over warfarin in non-valvular AF [January CT, JACC 2019]
- Decide on rhythm-control vs rate-control strategy in shared decision-making — early rhythm control may be preferred in some patients (EAST-AFNET 4 trial) [Kirchhof P, NEJM 2020]
- Investigate precipitants: TSH, electrolytes, alcohol use, sleep apnea screening
- Troponin to exclude NSTEMI given the lateral ST/T changes and risk profile
- Echocardiogram within 1–2 weeks for structural and functional assessment
- If > 48 h or unknown duration: do not cardiovert until anticoagulated for 3 weeks or TEE-guided
Key Questions for Your Physician
- Should I start an anticoagulant today, and which one is best for me?
- Do I need rate control alone, or should we attempt to restore normal rhythm?
- What investigations are planned (echo, blood tests, sleep study)?
- What signs would prompt me to return to the emergency department?
- How will my hypertension and diabetes management be coordinated with this new diagnosis?
What This Means for You
Your ECG shows atrial fibrillation — the upper chambers of your heart are beating in an irregular, disorganized way, and your overall heart rate is fast (138 beats per minute). This explains the palpitations and lightheadedness you have been feeling. The good news: your ECG does not show signs of a heart attack, your QT is normal, and your blood pressure and oxygen levels are reasonable.
There are two important things to address now:
1. Slowing the heart rate — usually with a beta-blocker or calcium channel blocker. This relieves symptoms and prevents the heart from being overworked.
2. Preventing stroke — atrial fibrillation increases the risk of stroke because blood can pool in the heart and form clots that travel to the brain. Based on your age and conditions (CHA₂DS₂-VASc score 4), blood-thinning medication (anticoagulation) is strongly recommended. Modern medications called DOACs (apixaban, rivaroxaban) are usually preferred over warfarin — fewer dietary and drug interactions, no routine blood tests required.
Your physician will arrange tests (blood work, an echocardiogram of the heart) and will discuss whether to focus on controlling the rate only or whether to also try to restore normal rhythm. Both are valid; the choice depends on your symptoms, preferences, and how the heart looks on the echocardiogram.
Seek emergency care immediately for chest pain, severe shortness of breath, fainting, or any sign of a stroke (sudden weakness, face droop, slurred speech, or severe headache).
High confidence in rhythm identification, axis, intervals, and risk-score calculation. ST/T-wave interpretation in tachycardic AF carries inherent uncertainty; troponin and post-rate-control ECG provide definitive clarification.
References
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J 2021;42(5):373–498.
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update on the 2014 Guideline for the Management of Patients With Atrial Fibrillation. JACC 2019;74(1):104–132.
- Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–72.
- Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. NEJM 2020;383(14):1305–1316.
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J 2019;40(3):237–269.